Catégorie : Digital Health

AMKBIOTECH

by jbertholdin Biotech, Digital Health, Pharma

AMKBIOTECH

About the company

AMKbiotech is an innovative service laboratory proving highplex tissue imaging solutions for biomarker identification and target efficacy validation.

About the solution

AMKbiotech combines the development of a novel tissue processing and imaging approach with AI-based analytical tools to generate 200 times more data from a single tissue section, while saving 80% of the resources needed for such analysis with classical histology approaches, in a 2 times faster execution period.

Website
Key information

–  Therapeutic areas: Histopathology, Oncology, Dermatology, Inflammatory disease

–  Based in: Sophia-Antipolis (FRANCE)

–  Employees: 1-10

–  Created in: 2021

ARIANA PHARMACEUTICALS

by jbertholdin Digital Health

ARIANA PHARMACEUTICALS

About the company

Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies.

Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals.

With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.

About the solution

Ariana Pharma has developed an explainable artificial intelligence platform which explores all possible biomarker associations, generating results that can be used directly to design clinical trials and accelerate drug development. Based on the mathematical theories of Formal Concept Analysis and Gallois lattices, the power of the KEM® platform lies in its ability to deliver explainable results from small cohorts. KEM® is also effective at managing contradictions and heterogeneous data, ensuring the identification of relevant and accurate hypotheses that meet the needs of precision medicine.

Website
Key information

–  Therapeutic areas: Oncology, CNS, Cardiometabolic, Immunology

–  Based in: Paris (FRANCE)

–  Employees: 11-50

–  Created in: 2003

ORAKL ONCOLOGY

by jbertholdin Biotech, Digital Health, Pharma

ORAKL ONCOLOGY

About the company

The current drug development process does not capture cancer complexity or heterogeneity. This is a main reason why 96% of drugs fail when they meet patients in clinical trials, lacking efficacy in the patient population.

Orakl Oncology stands at the forefront of the techbio landscape, pioneering the use of patient tumor avatars to meticulously accelerate and de-risk drug development in collaboration with oncology players.


As a spin-out from Gustave Roussy (2023), the 4th cancer center in the world, Orakl’s boasts unique access to a vast repository of patient tissue samples and associated data. This strategic foundation positions them to scale quickly across a vast number of cancer subtypes starting with colorectal and pancreatic cancers.

The founders and team collectively bring unparalleled expertise in cancer cell biology and engineering. With over 30 years of combined academic experience across France, the UK, and the US, they are dedicated to improving cancer treatment. The company has already been funded 5M€ in equity and grants for their first developments.

About the solution

Orakl Oncology is a techbio platform that is building a unique collection of patient tumor avatars, each of them combining the best biology and patient clinical and molecular data. As a spin-out from Gustave Roussy, the 4th cancer center in the world, they are positionned to scale quickly across a vast number of cancer subtypes starting with colorectal and pancreatic cancers. This combination of biology and data, scalable and supported by proprietary know-how, is an extraordinary differenciating factor.


Their cutting-edge approach involves the integration of functional testing and AI-powered analysis to predict patient response to treatments and stratify populations. They already obtained excellent predictive values, at the patient and population levels.


Orakl discovers and develops new drugs that will succeed in the clinic, for their own pipeline or in co-development with oncology companies.

Website
Key information

–  Therapeutic areas: Oncology

–  Based in: Paris (FRANCE)

–  Employees: 1-10

–  Created in: 2023

BRAINTALE

by jbertholdin Digital Health, Medtech

BRAINTALE

About the company

BrainTale is an innovative medtech company deciphering white matter to enable faster drug development and better brain care with clinically validated prognostic solutions. With non-invasive, sensitive and reliable measurements of white matter microstructure alterations, BrainTale offers a digital biomarkers platform to support clinical development programs and decision-making in clinical routine.

BrainTale enables the identification of patients at risk, early diagnosis and monitoring of disease progression and the effectiveness of treatments in neurology, in particular for demyelinating diseases such as Multiple Sclerosis and neurodegenerative diseases such as Alzheimer’s Diseases. Based on more than 15 years of research and development, BrainTale’s products are developed to meet the medical needs and expectations of pharma companies and healthcare professionals for the benefit of patients. 

About the solution

BrainTale’s solutions enable access to diffusion MRI markers for drug development and patient care, through a unique technology that enables calibration and standardization of MRI diffusion parameters in a multidevice and multicenter setting. Thus, BrainTale offers quantification of white matter tissue, especially fiber density, axonal degeneration and myelin content, with unlimited potential to support clinical development programs through accurate patient selection and stratification at inclusion, and evaluation of treatment efficacy with highly sensitive and robust biomarkers.

Website
Key information

–  Therapeutic areas: Neuroscience, Neurology, Alzheimer’s Disease, Multiple Sclerosis, Traumatic Brain Injury, Rare demyelinating diseases

–  Based in: Paris & Strasbourg (FRANCE)

–  Employees: 11 – 50

–  Created in: 2018

IKTOS

by jbertholdin Biotech, Digital Health, Pharma

IKTOS

About the company

Incorporated in October 2016, Iktos is a French start-up company specialized in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design.

Iktos is developing a proprietary and innovative solution based on deep generative models, which enables, using existing data, to design molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project.

The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos is also developing Iktos Robotics, a unique AI-driven synthesis automation platform which dramatically accelerates the Design-Make-Test cycle in drug discovery.

About the solution

Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos is also developing Iktos Robotics, a unique AI-driven synthesis automation platform which dramatically accelerates the Design-Make-Test cycle in drug discovery.

Iktos offers the possiblity to its partners to use it unique technology via proprietary SaaS software platforms: Makya for de novo generative design and Spaya for retrosynthesis and synthetic access. Its partners can also rely on Iktos expertise to run integrated drug discovery projects from hit discovery, hit-to-lead, lead optimization, all the way down to preclinical drug candidate.

Website
Key information

–  Therapeutic areas: Any therapeutic areas including oncology, CNS / neurology, Immunology, Infectious diseases, Rare diseases

–  Based in: Headquarters and lab: Paris (FRANCE)
Additional offices: US and JAPAN

–  Employees: 51 – 200

– Created in: 2016

CONTACT
Bose AvirupChief Business Officer

avirup.bose@iktos.com